68Ga-DOTA-exendin-4 PET/CT for Insulinoma Localization in Patients with Negative or Inconclusive Conventional Imaging
A specialized scan finds insulinomas in 72% of patients when standard imaging fails, potentially sparing them from exploratory surgery.
In a real-world dual-center study of 101 patients with endogenous hyperinsulinemic hypoglycemia, [68Ga]Ga-DOTA-exendin-4 PET/CT demonstrated a 72% insulinoma detection rate when conventional imaging was negative or inconclusive, with 93.8% surgical sensitivity. These findings establish GLP-1R-targeted PET/CT as a clinically meaningful rescue imaging modality that changes surgical management for a potentially curable but diagnostically challenging rare tumor.
What the study was
- Study design
- Retrospective dual-center real-world imaging study
- Population
- Patients with biochemically proven endogenous hyperinsulinemic hypoglycemia with negative/inconclusive conventional imaging
- Sample size
- 101
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- J Clin Endocrinol Metab
Why it surfaced
GLP-1R PET/CT as rescue imaging for insulinoma is clinically actionable and changes surgical management; real-world dual-center study with 101 patients; high unmet need as insulinoma is curable with surgery but missed by conventional imaging.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.